English
Home > Products > CAS:17183-98-1

China CAS:17183-98-1 Manufacturer

Our pros are reduce price ranges,dynamic gross sales staff,specialized QC,potent factories,premium quality services for CAS:17183-98-1, We welcome all with the consumers and pals to call us for mutual positive aspects. Hope to do additional company along with you.
CAS:17183-98-1, We are eager to cooperate with foreign companies which care much on the real quality, stable supply, strong capability and good service. We can offer the most competitive price with high quality,because we are much MORE PROFESSIONAL. You are welcomed to visit our company at any time.

Related Products

Hot Products

  • Budesonide

    Budesonide

    Budesonide has USP, EP specifications. CEP, GMP and FDA approved.

    CAS:51333-22-3

  • 16alpha-Hydroxyprednisolone

    16alpha-Hydroxyprednisolone

    16alpha-Hydroxyprednisolone has DMF available.

    CAS:13951-70-7

  • 17a-Hydroxyprogesterone Acetate

    17a-Hydroxyprogesterone Acetate

    17a-Hydroxyprogesterone Acetate is an endogenous progesteroid hormone similar to progesterone.

    CAS:302-23-8

  • Mono-acetyl Ganciclovir

    Mono-acetyl Ganciclovir

    Mono-acetyl Ganciclovir Specification: Min 97.0%

    CAS:88110-89-8

  • Mifepristone Capsules

    Mifepristone Capsules

    Mifepristone Capsules Specifications：10mg*1
    Indications：Emergency Contraceptive
  • 16alpha-Hydroxyprednisolone Acetate

    16alpha-Hydroxyprednisolone Acetate

    16alpha-Hydroxyprednisolone Acetate is used to observe interaction of some steroid drugs with β-cyclodextrin polymer to calculate the relative strengh of interaction between the hydrophobicity parameters of the drugs and the strenght of the drug-β-​cyclodextrin polymer.

    CAS:86401-80-1

  • Related Blog
  • Reviews

  • 2024 CPhI Exhibition Shanghai

    In 2024, CPhI China will continue to be a unique opportunity for global pharmaceutical companies, manufacturers and suppliers. We will be waiting for you at the W1G20 booth on time to explore and interpret new trends in the pharmaceutical industry and interact with each other to further expand their business cooperation and various business opportunities. See you in Shanghai!

  • Gedian Humanwell successfully passed the EDQM audit

    The API -- cyproterone acetate, successfully passed the EU-GMP audit in April 2024.

  • CPHI & PMEC China 2024 Ended Successfully

    From June 19 to 21, the 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2024), organized by Informa Markets and China Chamber of Commerce for Import and Export of Pharmaceutical and Health Products and co-organized by Shanghai Bohua International Exhibition Co., LTD., was held in Shanghai. Nearly 3,500 well-known exhibitors at home and abroad gathered in Shanghai New International Expo Center (Pudong), attracting more than 60,000 professional buyers from more than 150 countries and regions, and a total of more than 90,000 industry colleagues to participate in the event.

  • Welcome to IPhEB Russia 2024

    IPhEB Russia 2024 will be held at International Exhibition Centre“Crocus Expo”from November 19 to 22, our booth number is B9023.

  • What are the categories of pharmaceutical intermediates?

    Pharmaceutical intermediates are classified by therapeutic areas, chemical structures, synthesis stages and production technologies, covering multiple types such as anti-tumor and anti-infection. They are key precursors in the synthesis of active pharmaceutical ingredients.

  • Are There Any Side Effects or Risks Associated with Levonorgestrel Capsules

    As a leading provider in women's reproductive health, we at Humanwell often receive questions from individuals considering emergency contraception. One of the most frequent and important queries we encounter is about the safety profile of Levonorgestrel Capsules.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept